The duration of the motor response to apomorphine boluses is conditioned by the length of a prior infusion in Parkinson's disease

Movement Disorders

Volumn 24, Issue 5, 2009, Pages 762-766

  Vaamonde, Julia ^a,b,c   Flores, José M ^a,b   Weisser, Roberto ^a,b   Ibañez, Ramón ^a,b   Obeso, José A ^a,b  

^a Hospital General   (Spain)

^b UNIVERSITY CLINIC OF NAVARRA   (Spain)

^c NONE   (Spain)

Author keywords

Apomorphine boluses; Apomorphine infusion; Motor complications; Pharmacological tolerance

Indexed keywords

APOMORPHINE; BROMOCRIPTINE; DOMPERIDONE; LEVODOPA; PRAMIPEXOLE; ROPINIROLE; DOPAMINE RECEPTOR STIMULATING AGENT;

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG TOLERABILITY; DYSKINESIA; EVOKED MUSCLE RESPONSE; FEMALE; HUMAN; MALE; MORNING DOSAGE; MOTOR DYSFUNCTION; PARKINSON DISEASE; PRIORITY JOURNAL; SINGLE DRUG DOSE; TREATMENT DURATION; TREATMENT RESPONSE; CLINICAL TRIAL; DRUG ADMINISTRATION; DRUG EFFECT; HOSPITALIZATION; MOTOR ACTIVITY; PATHOPHYSIOLOGY; TIME;

APOMORPHINE; DOPAMINE AGONISTS; DRUG ADMINISTRATION SCHEDULE; HUMANS; MOTOR ACTIVITY; PARKINSON DISEASE; SEVERITY OF ILLNESS INDEX; TIME FACTORS;

EID: 67651163648     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.22234     Document Type: Article

References (37)

1. Frey KA. The neurochemistry of therapeutics: levodopa pharmacodynamics in Parkinson's disease. Ann Neurol 2001; 49: 285-287.
2. Olanow CW,Obeso JA,Stocchi F. Continuos dopamine-receptor treatment of Parkinson's disease: scientific rationale and clinical implications. Lancet Neurol 2006; 5: 677-687.
3. Shrag A,Quinn N. Dyskinesias and motor fluctuations in Parkinson's disease. A community-based study. Brain 2000; 123: 2297-3005.
4. Fabbrini G,Mourandian MM,Juncos JL,Schlegel I,Mohr E,Chase TN. Motor fluctuation in Parkinson's disease: central pathophysiological mechanisms. I. Ann Neurol 1988; 24: 366-371.
5. De la fuente-Fernández R,Lu J-Q,Sois V, et al. Biochemical variations in the synaptic level of dopamine precede motor fluctuations in Parkinson's disease: PET evidence of increased dopamine turnover. Ann Neurol 2001; 49: 298-303.
6. Mourandian MM,Chase TN. Central mechanisms and levodopa response fluctuations in Parkinson's disease. Clin Neuropharmacol 1988; 11: 378-385.
7. Roach ES. Both postsynaptic and presynaptic dysfunction contribute to Parkinson's disease. Arch Neurol 2007; 64: 143.
8. Guttman M,Seeman P,Reynolds GP,Riederer P,Jellinger K,Tourtelotte WW. Dopamine D2 receptor density remains constant in treated Parkinson's disease. Ann Neural 1986; 19: 487-492.
9. Chase TN,Baronti F,Fabbrini G, et al. Rationale for continuous dopamimetic therapy of Parkinson's disease. Neurology 1989; 39: 7-10.
10. Obeso JA,Grandas F,Herrero MT,Horowski R. The role of pulsatile versus continuous dopamine receptor stimulation for functional recovery in Parkinson's disease. Eur J Neurosci 1994; 6: 889-897.
11. Blanchet PJ,Calon F,Martel JC, et al. Continuous administration decreases and pulsatile administration increases behavioral sensitivity to a novel dopamine D2 agonist (U-91356A) in MPTP-exposed monkeys. J Pharmacol Exp Ther 1995; 272: 854-859.
12. Nutt JG,Obeso JA,Stochi F. Continuous dopamine-receptor stimulation in advanced Parkinson's disease. Trends Neurosci 2000; 23: S109-S115.
13. Bibbiani F,Constantini LC,PateI R,Chase TN. Continuous dopaminergic stimulation reduces risk of motor complications in parkinsonian primates. Exp Neurol 2005; 192: 73-78.
14. Olanow CW,Obeso JA,Stochhi F. Continuous dopaminergic stimulation in the treatment of Parkinson's disease. Nat Clin Pract Neurol 2006; 2: 382-392.
15. Nutt JG. Continuous dopaminergic stimulation: is it the answer to the motor complications of levodopa? Mov Disord 2007; 22: 1-9.
16. Grandas F,Obeso JA. Motor response following repeated apomorphine administration is reduced in Parkinson's disease. Clin Neurpharmacol 1989; 12: 14-22.
17. Luquin MR,Laguna J,Herrero MT,Obeso JA. Behavioral tolerante to repeated apomorphine administration in parkinsonian monkeys. J Neurol Sci 1993; 114: 40-44.
18. Nutt J,Gancher S,Woodward W. Does and inhibitory action of levodopa contribute to motor fluctuations? Neurology 1988; 38: 1533-1557.
19. De la fuente-Fernández R,Schulzer M,Mak E,Calme DB,Stoessl AJ. Presynaptic mechanisms of motor fluctuations in Parkinson's disease: a probabilistic model. Brain 2004; 127: 888-899.
20. Vaamonde J,Luquin MR,Obeso JA. Levodopa consumption reduce dopaminergic receptor responsiveness in Parkinson's disease. Clin Neuropharmacol 1989; 12: 271-284.
21. Grandas F,Gancher J,Lera G, et al. Time interval between repeated injections conditions the duration of motor improvement in Parkinson's disease. Neurology 1992; 42: 1287-1290.
22. Stewart A,Factor DO. Intermittent subcutaneous apomorphine therapy in Parkinson's disease. Neurology 2004; 62(Suppl): S12-S17.
23. Bowron ANP. Practical considerations in the use of apomorphine injectable. Neurology 2004; 62(Suppl): S32-S36.
24. Sage J,Trooskim S,Sonsalla P,Heikkila R,Duvoisin R. Long-term duodenal infusion of levodopa for motor fluctuations in Parkinsonism. Ann Neurol 1988; 24: 87-89.
25. Stocchi F,Vacca I,De Pandis MF,Barnato L,Valente M,Ruggieri S. Subcutaneous continuous apomorphine infusion in fluctuating patients with Parkinson's disease: long-term results. J Neurol Sci 2001; 22: 93-94.
26. Vaamonde J,Luquín MR,Obeso JA. Subcutaneous lisuride infusion in Parkinson's disease: response to chronic administration in 34 patients. Brain 1991; 114: 601-614.
27. Stocchi F,Ruggieri S,Vacca L,Olanow CW. Prospective randomized trial of lisuride infusion versus oral levodopa in patients with Parkinson's disease. Brain 2002; 125: 2058-2066.
28. Juncos JL,Engber T,Raisman R, et al. Continuos and intermittent levodopa differentially affect basal ganglia function. Ann Neurol 1989; 25: 473-478.
29. Obeso JA,Rodriguez-Oroz M,Marin C, et al. The origin of motor fluctuations in Parkinson's disease: importance of dopaminergic innervatin and basal ganglio circuits. Neurology 2004; 62(Suppl 1): S17-S30.
30. Merello M,Balej J,Delfino M,Cammarota A,Betti O,Leiguarda R. Apomorphine induces changes in GPi spontaneous outflow in patients with Parkinson's disease. Mov Disord 1999; 14: 45-49.
31. Papa S,Desimore R,Fiorani M,Oldfield EH. Internal globus pallidus discharge is nearly suppressed during levodopa-induced dyskinesias. Ann Neurol 1999; 46: 732-738.
32. Lozano AM,Lang AE,Levy R,Hutchinson W,Dostrovky J. Neural recordings in Parkinson's disease patients with dyskinesias induced by apomorphine. Ann Neurol 2000; 47: S141-S146.
33. Alonso-Frenc F,Zamarbide I,Adegre M, et al. Slow oscillatory activity and levodopa-induced dyskinesias in Parkinson's disease. Brain 2006; 129: 748-757.
34. Boraud T,Bezard E,Bioulac B,Gross CE. Dopamine agonist-induced dyskinesias are correlated to both firing pattern and frequency alterations of pallidal neurons in the MPTP-treated monkey. Brain 2001; 124: 546-557.
35. Vila M,Levy R,Herrero MT, et al. Metabolic activity of the basal ganglia in parkinsonian syndromes in humans and non humans primates: a cytochrome oxidase histochemistry study. Neuroscience 1996; 71: 903-912.
36. Obeso JA,Rodriguez-Oroz MC,Rodriguez M, et al. Pathophysiology of the basal ganglia in Parkinson's disease. Trends Neruosci 2000; 23: S8-S19.
37. Cedarbaum JM,Silvestri M,Kutt H. Sustained enteral adminstration of levodopa increases and interrupted infusion decreases levodopa dose requirements. Neurology 1990; 40: 995-997.